0001558370-22-010236.txt : 20220623 0001558370-22-010236.hdr.sgml : 20220623 20220623173032 ACCESSION NUMBER: 0001558370-22-010236 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220622 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20220623 DATE AS OF CHANGE: 20220623 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sigilon Therapeutics, Inc. CENTRAL INDEX KEY: 0001821323 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474005543 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39746 FILM NUMBER: 221036455 BUSINESS ADDRESS: STREET 1: 100 BINNEY STREET STREET 2: STE 600 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-336-7540 MAIL ADDRESS: STREET 1: 100 BINNEY STREET STREET 2: STE 600 CITY: CAMBRIDGE STATE: MA ZIP: 02142 8-K 1 sgtx-20220622x8k.htm 8-K
0001821323false00018213232022-06-222022-06-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 22, 2022

SIGILON THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-39746

47-4005543

(State or other jurisdiction

(Commission

(IRS Employer

of incorporation)

File Number)

Identification No.)

100 Binney Street, Suite 600, Cambridge, MA

02142

(Address of principal executive offices)

(Zip Code)

(Registrant’s telephone number, including area code): (617) 336-7540

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Trading

Name of each exchange

Title of each class

    

Symbol(s)

    

on which registered

Common Stock, $0.001 par value per share

SGTX

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On June 22, 2022, Sigilon Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based on the closing bid price of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for the last 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Select Market. Nasdaq Listing Rule 5450(a) requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive business days.

The Notice has no immediate effect on the listing of the Company’s Common Stock on The Nasdaq Global Select Market. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days from receipt of the Notice, or until December 19, 2022, to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company’s Common Stock must be at least $1.00 per share for a minimum of 10 consecutive business days prior to December 19, 2022, unless Nasdaq exercises its discretion to extend this period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). There can be no assurance the Company will be able to regain compliance.

If the Company does not regain compliance by December 19, 2022, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company must submit an application to transfer to The Nasdaq Capital Market and will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the requirement that listed securities maintain a Minimum Bid Price. The Company would also need to provide written notice of its intention to cure the deficiency during the second 180 calendar day compliance period, such as by effecting a reverse stock split, if necessary.

If the Company does not regain compliance within the compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company’s Common Stock will be subject to delisting. The Company can seek review of the delisting determination by a hearing panel and also appeal a decision of such hearing panel to the Nasdaq Listing and Hearing Review Council. There can be no assurance that, if the Company decides to appeal the delisting determination, such appeal would be successful.

The Company intends to monitor the closing bid price of the Company’s Common Stock and consider its available options to resolve the noncompliance with the Minimum Bid Price Requirement, including, subject to approval of the Company’s Board of Directors and stockholders, implementing a reverse stock split. There can be no assurance that a reverse stock split would be approved or would result in a sustained higher stock price that would allow the Company to meet the Minimum Bid Price Requirement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SIGILON THERAPEUTICS, INC.

By:

/s/ Matthew P. Kowalsky

Matthew P. Kowalsky

Chief Legal & Admin Officer and Corporate Secretary

Date: June 23, 2022

EX-101.SCH 2 sgtx-20220622.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 sgtx-20220622_lab.xml EX-101.LAB EX-101.PRE 4 sgtx-20220622_pre.xml EX-101.PRE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information
Jun. 22, 2022
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Jun. 22, 2022
Entity File Number 001-39746
Entity Registrant Name SIGILON THERAPEUTICS, INC.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 47-4005543
Entity Address, Address Line One 100 Binney Street
Entity Address, Adress Line Two Suite 600
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code 617
Local Phone Number 336-7540
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol SGTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001821323
Amendment Flag false
XML 6 sgtx-20220622x8k_htm.xml IDEA: XBRL DOCUMENT 0001821323 2022-06-22 2022-06-22 0001821323 false 8-K 2022-06-22 SIGILON THERAPEUTICS, INC. DE 001-39746 47-4005543 100 Binney Street Suite 600 Cambridge MA 02142 617 336-7540 false false false false Common Stock, $0.001 par value per share SGTX NASDAQ true false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 24 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.sigilon.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports sgtx-20220622x8k.htm sgtx-20220622.xsd sgtx-20220622_lab.xml sgtx-20220622_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sgtx-20220622x8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "sgtx-20220622x8k.htm" ] }, "labelLink": { "local": [ "sgtx-20220622_lab.xml" ] }, "presentationLink": { "local": [ "sgtx-20220622_pre.xml" ] }, "schema": { "local": [ "sgtx-20220622.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "sgtx", "nsuri": "http://www.sigilon.com/20220622", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "sgtx-20220622x8k.htm", "contextRef": "Duration_6_22_2022_To_6_22_2022_uKkQ0B2ddUueTnKocet_xA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "sgtx-20220622x8k.htm", "contextRef": "Duration_6_22_2022_To_6_22_2022_uKkQ0B2ddUueTnKocet_xA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Adress Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sigilon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 13 0001558370-22-010236-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-22-010236-xbrl.zip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end